A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice

Wui, Seo Ri; Kim, Hye Kyeong; Han, Ji Eun; Kim, Jong Min; Kim, Yeon Hee; Chun, Jeong Hoon; Cho, Yang Je; Lee, Na Gyong

doi:10.1016/j.intimp.2011.03.020

Cited by 15 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to MPL, CIA05 is a TLR4 agonist purified from an Escherichia coli strain that expresses lipopolysaccharides with short carbohydrate chains and detoxified by alkaline hydrolysis [11]. CIA05 stimulates the secretion of various cytokines and chemokines from human monocytes and mouse bone-marrow dendritic cells (DCs), and the immuno-stimulatory activity of CIA05 is higher than that of MPL [11]. Therefore, in the current study, we tested the efficacy of HSP90-E6 TB vaccine with CIA05 instead of MPL adjuvant.…”

Section: Introductionmentioning

confidence: 99%

Antigen-Specific IFN-γ/IL-17-Co-Producing CD4+ T-Cells are the Determinants for Protective Efficacy of Tuberculosis Subunit Vaccine

et al. 2020

View full text Add to dashboard Cite

The antigen-specific Th17 responses in the lungs for improved immunity against Mycobacterium tuberculosis (Mtb) infection are incompletely understood. Tuberculosis (TB) vaccine candidate HSP90-ESAT-6 (E6), given as a Bacillus Calmette-Guérin (BCG)-prime boost regimen, confers superior long-term protection against the hypervirulent Mtb HN878 infection, compared to BCG or BCG-E6. Taking advantage of protective efficacy lead-out, we found that ESAT-6-specific multifunctional CD4+IFN-γ+IL-17+ T-cells optimally correlated with protection level against Mtb infection both pre-and post-challenge. Macrophages treated with the supernatant of re-stimulated lung cells from HSP90-E6-immunised mice significantly restricted Mtb growth, and this phenomenon was abrogated by neutralising anti-IFN-γ and/or anti-IL-17 antibodies. We identified a previously unrecognised role for IFN-γ/IL-17 synergism in linking anti-mycobacterial phagosomal activity to enhance host control against Mtb infection. The implications of our findings highlight the fundamental rationale for why and how Th17 responses are essential in the control of Mtb, and for the development of novel anti-TB subunit vaccines.

show abstract

Section: Introductionmentioning

confidence: 99%

Antigen-Specific IFN-γ/IL-17-Co-Producing CD4+ T-Cells are the Determinants for Protective Efficacy of Tuberculosis Subunit Vaccine

et al. 2020

View full text Add to dashboard Cite

show abstract

“…CIA06, like CIA09, is a dLOS-based adjuvant formulation with aluminum hydroxide instead of liposomes as the antigen carrier [38,39]. CIA06 enhances the serum antibody and CMI responses to vaccines against anthrax, influenza, Pseudomonas, and HPV [38][39][40][41], inducing protective antibodies as demonstrated by neutralization assays and challenges in model animals [38][39][40][41].…”

Section: Discussionmentioning

confidence: 99%

“…It induces the secretion of cytokines from murine peritoneal macrophages similarly to MPL but with more potent activation of human monocytes and DCs [37]. dLOS in combination with aluminum hydroxide (designated CIA06) has adjuvant activity in several viral and bacterial vaccines [38][39][40][41][42] and performed well in a phase I clinical study of a CIA06-adjuvanted human papillomavirus (HPV) virus-like particle (VLP) vaccine (unpublished data). We developed cationic liposome-based adjuvant CIA09, composed of DOTAP-based cationic liposomes and dLOS, which enhances antibody and cell-mediated immune responses to recombinant tuberculosis antigens, inactivated Japanese encephalitis vaccine (JEV), and recombinant varicella-zoster virus (VZV) glycoprotein E (gE) antigen [42][43][44].…”

Section: Introductionmentioning

confidence: 99%

The Effect of a TLR4 Agonist/Cationic Liposome Adjuvant on Varicella-Zoster Virus Glycoprotein E Vaccine Efficacy: Antigen Presentation, Uptake, and Delivery to Lymph Nodes

Wui

Ryu

et al. 2021

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Adjuvant CIA09, composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-based cationic liposomes and the toll-like receptor 4 agonist de-O-acylated lipooligosaccharide (dLOS), has been shown to enhance antibody and cellular immune responses to varicella-zoster virus (VZV) glycoprotein E (gE), recombinant tuberculosis vaccine antigen, and inactivated Japanese encephalitis vaccine. In this study, we investigated its modes of action using VZV gE as a model antigen. Liposomes adsorbed gE and cooperatively with dLOS promoted endocytosis-mediated cellular uptake of gE by mouse dendritic cells in vitro. CIA09 increased the stability and cellular uptake of the antigen at the muscle site of injection, and induced immune cell recruitment and cytokine and chemokine production, which led to efficient antigen delivery to draining lymph nodes. Mouse bone marrow-derived dendritic cells, pulsed with CIA09-adjuvanted gE, efficiently presented gE to antigen-specific T cells, inducing Th1-type biased immunity, as shown by high IFN-γ production. The data indicate that liposomes and dLOS cooperate in the adjuvant activity of CIA09 by promoting antigen uptake and delivery to lymph nodes as well as antigen presentation to T cells.

show abstract

“…The combination also led to increased IL-4 secretion and GL7 expression. Thus, combination of CIA05 with alum could be used to achieve higher immune responses to PA, leading to the development of an effective anthrax vaccine [60].…”

Section: Improved Pa Vaccinesmentioning

confidence: 99%

Recent progress in the development of anthrax vaccines

Kaur¹,

Bhatnagar

2011

BIOT

View full text Add to dashboard Cite

Bacillus anthracis is the etiological agent of anthrax. Although anthrax is primarily an epizootic disease; humans are at risk for contracting anthrax. The potential use of B. anthracis spores as biowarfare agent has led to immense attention. Prolonged vaccination schedule of current anthrax vaccine and variable protection conferred; often leading to failure of therapy. This highlights the need for alternative anthrax countermeasures. A number of approaches are being investigated to substitute or supplement the existing anthrax vaccines. These relied on expression of Protective antigen (PA), the key protective immunogen; in bacterial or plant systems; or utilization of attenuated strains of B. anthracis for immunization. Few studies have established potential of domain IV of PA for immunization. Other targets including the spore, capsule, S-layer and anthrax toxin components have been investigated for imparting protective immunity. It has been shown that co-immunization of PA with domain I of lethal factor that binds PA resulted in higher antibody responses. Of the epitope based vaccines, the loop neutralizing determinant, in particular; elicited robust neutralizing antibody response and conferred 97% protection upon challenge. DNA vaccination resulted in varying degree of protection and seems a promising approach. Additionally, the applicability of monoclonal and therapeutic antibodies in the treatment of anthrax has also been demonstrated. The recent progress in the direction of anthrax prophylaxis has been evaluated in this review.

show abstract

A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice

Cited by 15 publications

References 37 publications

Antigen-Specific IFN-γ/IL-17-Co-Producing CD4+ T-Cells are the Determinants for Protective Efficacy of Tuberculosis Subunit Vaccine

Antigen-Specific IFN-γ/IL-17-Co-Producing CD4+ T-Cells are the Determinants for Protective Efficacy of Tuberculosis Subunit Vaccine

The Effect of a TLR4 Agonist/Cationic Liposome Adjuvant on Varicella-Zoster Virus Glycoprotein E Vaccine Efficacy: Antigen Presentation, Uptake, and Delivery to Lymph Nodes

Recent progress in the development of anthrax vaccines

Contact Info

Product

Resources

About